Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.31 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492624 | 0.89 | DDR1 (0.39) | PLOD2DDR1LMNAMEN1MAPT | |
| SCHEMBL1492571 | 0.84 | CCR2 (0.36) | LMNAMEN1MAPTKMT2AHPGD | |
| SCHEMBL1492561 | 0.81 | CES1 (0.39) | LMNAMEN1KMT2AHPGD | |
| SCHEMBL1492567 | 0.81 | HDAC6 (0.40) | PLOD2MAPTNR3C2NR3C1PGR | |
| SCHEMBL14340600 | 0.79 | RIPK1 (0.40) | PLOD2DDR1LMNAMAPTNR3C2 | |
| SCHEMBL1492608 | 0.79 | PLOD2 (0.38) | PLOD2MAPTRAB9AKMT2ANR3C2 | |
| SCHEMBL10254048 | 0.79 | PLOD2 (0.38) | PLOD2NR3C2NR3C1PGRHPGD | |
| SCHEMBL1492615 | 0.78 | KEAP1 (0.42) | PLOD2LMNAMEN1KMT2ANR3C2 | |
| SCHEMBL379406 | 0.78 | NR3C1 (0.48) | PLOD2NR3C2NR3C1PGR | |
| SCHEMBL10313445 | 0.78 | NR3C1 (0.44) | PLOD2NR3C2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-2300472-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009149139-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | PLOD2 3974/4885DDR1 1723/4885LMNA 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.